Last updated: June 27, 2026
Pfizer’s suit against Mylan Laboratories Limited (Delaware, 2015, case 1:15-cv-00026-SLR-SR) is an ANDA patent case tied to Pfizer’s branded drug(s) and Mylan’s generic certification. The public docket and filings for this specific case number determine the claims, asserted patents, defenses, claim construction outcomes, and any settlement or stipulated dismissal. Without the underlying docket documents, the asserted patents, holdings, and the commercial impact cannot be stated accurately.
What patents were asserted in Pfizer v. Mylan Laboratories Limited 1:15-cv-00026-SLR-SR?
No complete, case-specific litigation record is provided here. A patent-by-patent summary (numbers, titles, expiration dates, asserted claims, and infringement theories) requires the actual complaint, amended complaint, and court orders for 1:15-cv-00026-SLR-SR.
Which Pfizer patents are typically at issue in ANDA cases like this?
- Drug substance patents
- Drug product/formulation patents
- Method-of-use patents
- Orange Book listed patents covering specific strengths, dosage forms, or controlled-release profiles
- Final judgment and claim-construction decisions often hinge on whether generic design-around practices avoid specific claim limitations
What claims did Mylan Laboratories Limited challenge in the asserted patents?
A technical infringement analysis requires: (i) Mylan’s answer, (ii) its invalidity contentions (IPR/anticipation/obviousness grounds), (iii) claim-construction briefs, and (iv) expert reports cited in summary judgment or trial. Those documents are not included in the prompt.
How do these cases typically break down procedurally?
- Plead infringement and invalidity early
- Court issues claim construction
- Parties move for summary judgment on infringement and/or invalidity
- Case resolves via judgment, settlement, or dismissal
What were the key procedural milestones and court rulings?
Procedural milestones require docket entries and specific dates (motions to dismiss, Markman schedule, summary judgment dates, trial dates, final judgment, and any stay lifts). None are provided for 1:15-cv-00026-SLR-SR in the request.
What orders usually drive the outcome in Delaware ANDA patent cases?
- Claim construction (Markman)
- Motions regarding domestic industry and standing (if applicable)
- Determinations on anticipated/obvious combinations
- Willfulness or damages motions (if case proceeds to damages)
- Scheduling and stay enforcement under the Hatch-Waxman framework
Did the case reach a trial, summary judgment, or final judgment?
A litigation outcome summary requires the final disposition: jury verdict, bench decision, consent judgment, or stipulated dismissal, plus any non-infringement/invalidity findings.
What would “winning” look like in this docket type?
- Judgment of non-infringement for Mylan
- Judgment of invalidity for the asserted patents
- A mixed outcome with partial survivals (rare without full records)
- Settlement and stipulated dismissal often ends with a license and/or delayed generic entry
Did Pfizer and Mylan settle, and what was the effect on generic entry?
Settlement impact requires the settlement agreement terms as reflected in docket orders: date of dismissal, entry date commitment, license scope, and any carve-outs (including design-around approvals).
What settlement terms matter most commercially?
- Stated or de facto launch date
- Scope: product strength, dosage form, labeling carve-outs
- Royalties or lump sum
- Design-around restrictions and dispute resolution
- Provisions addressing future patent additions or continuation patents
How strong was Pfizer’s patent estate in this case based on the rulings?
Patent-strength conclusions require analysis of judicial findings on claim construction, infringement, and validity.
What evidence typically supports “strength” in ANDA cases?
- Claim construction favoring the patentee on critical limitations
- Narrow or non-obvious interpretations
- Prior art distinguishability in obviousness analysis
- Lack of enablement or anticipation gaps
- Consistent expert testimony aligning with the court’s claim reading
What generic entry risks existed for Mylan depending on the outcome?
Entry-risk profiling requires knowledge of:
- Which Orange Book patents were asserted and survived
- Whether the court entered injunctions or stayed launches
- Whether there were any 365-day exclusivity effects (if tied to paragraph IV notice practice)
- Final judgment timing relative to FDA approval and launch readiness
How do 365-day exclusivity and paragraph IV posture usually interact?
- Earlier first-filer status can create a regulatory exclusivity “block” even if patent positions remain contested
- Subsequent paragraph IV filers may face different launch timing depending on exclusivity expiration and court stays
What is the Orange Book status for Pfizer’s patents at issue in this case?
Orange Book status analysis requires the specific drug name and the patents asserted in 1:15-cv-00026-SLR-SR. This request does not specify:
- the active ingredient
- the NDA/BLA
- the Orange Book listed patents
- the listed expiration dates and patent types
How does this case compare with other Pfizer v. Mylan ANDA litigations?
A credible comparative analysis requires a list of other Mylan litigations by Pfizer with:
- similar asserted patent families
- similar claim-construction trends
- similar settlement patterns
- consistent drug products and dosage forms
No such dataset is included.
What commercial and regulatory exposure did this litigation create for Pfizer?
Commercial exposure depends on:
- the branded drug’s revenue concentration at the time
- whether the case blocked launch of a first or subsequent generic
- expected switching rates and formulary dynamics
- how much time remained on key exclusivity and patent terms
The request does not include the branded drug identity or any financial/revenue details.
Key Takeaways
- A reliable litigation summary for Pfizer Inc. v. Mylan Laboratories Limited, 1:15-cv-00026-SLR-SR, requires the complaint, asserted patent list, docket milestones, and final disposition.
- The case number alone is insufficient to produce a patent-level and outcome-level analysis with high confidence.
- No asserted-patent, ruling, or settlement terms can be stated accurately from the information provided.
FAQs
1) What court handled Pfizer v. Mylan Laboratories Limited 1:15-cv-00026-SLR-SR and what does “SLR-SR” indicate?
Delaware federal court with judge identifiers encoded in the docket caption.
2) Does this case involve an ANDA paragraph IV certification?
Typically yes in Pfizer vs. Mylan ANDA patent dockets, but the exact certification posture is not provided here.
3) Which patents are usually asserted in Pfizer v. Mylan drug-product disputes?
Commonly Orange Book listed formulation, method-of-use, or drug substance patents, depending on the branded product’s patent portfolio.
4) What determines whether Mylan could launch despite litigation?
Court-issued injunctions or stays, patent expiration/invalidity outcomes, and any settlement-driven entry dates.
5) How can the litigation outcome affect FDA labeling and launch timing?
Through design-around requirements, negotiated labeling positions, and the launch dates tied to final orders or settlement terms.
References
- U.S. District Court for the District of Delaware, Civil Action No. 1:15-cv-00026-SLR-SR (case caption provided in prompt).
